Medinol U.S. Commercializes Novel Coronary Stent
December 1, 2015
PARSIPPANY, N.J., – During the recent 2015 Transcatheter Cardiovascular Therapeutics Meeting held in San Francisco, CA, Medinol Ltd. continued to introduce novel stent solutions to the coronary marketplace. During a satellite symposium, “The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis”, a renowned physician panel discussed the key attributes of the currently available Medinol NIRxcell™ CoCr Coronary Stent System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved). Physician faculty included David E. Kandzari, MD – Piedmont Heart Institute, Jim Zidar, MD – North Carolina Heart and Vascular, Rajiv Jauhar, MD – North Shore University Medical Center, Peter Smits, MD – Maasstad Ziekenhuis, Rotterdam, the Netherlands and Shmuel Banai, MD – The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Discussion highlighted key product features and emphasized the unique design of the BIONICS/NIREUS clinical trials that have recently completed enrollment. Dr. Kandzari commented, “The delivery system is unlike any other product on the market” and Medinol’s approach to trial design “was entirely unlike any other pivotal trial as it included a ‘more comers’ patient population.”
Medinol U.S. recently opened their commercial business in Parsippany, NJ followed by the launch of NIRxcell CoCr Stent System. Matt Donnelly – U.S. General Manager commented, “Our goal is to provide optimal solutions for patient treatments through innovative product designs, novel and efficient manufacturing processes and robust clinical data. We believe that this is a winning combination to drive a product portfolio that will offer value to patients, physicians and healthcare facilities.”
On an annual basis, approximately 800,000 patients undergo coronary stenting procedures in the US. Healthcare providers continue to look for novel, effective and efficient solutions to treat their patients, leaving room for new entrants with innovative products to enter the market. Medinol has been at the forefront of innovation for years, and thus is well positioned to deliver an optimal portfolio to the marketplace beginning with the introduction of their NIRxcell CoCr Stent System. In an interview, Marty Leon, MD – Director of the Center for Interventional Vascular Therapy at New York-Presbyterian/ Columbia University Medical Center stated “We will never stop innovating and Medinol has been a prototype company that has been synonymous with continuous innovation.” Following link (http://www.medinol.com/?video=1) will allow you to hear Dr. Leon’s actual interview, including his thoughts on the ongoing development needs within the coronary stent marketplace.
Medinol LTD, headquartered in Israel with U.S. commercial offices in Parsippany, NJ, is dedicated to the science of cardiovascular intervention. For over 20 years, in-house research, development, and manufacturing have continuously raised the bar for quality and performance of stenting systems. In 2014 Medinol established its first sales office in the US and launched its first product sold directly to hospitals, a bare metal stent called NIRxcell™. With over two million stents deployed to date, their cutting-edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results, and their products constantly stretch the limits of innovation. For more information go to www.medinol.com.